Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Post Quarterly Sales of $5.29 Million

Equities analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to announce sales of $5.29 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Arrowhead Pharmaceuticals’ earnings. The lowest sales estimate is $3.50 million and the highest is $8.00 million. Arrowhead Pharmaceuticals posted sales of $40,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 13,125%. The company is expected to issue its next quarterly earnings report on Tuesday, August 8th.

On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $5.29 million for the current financial year, with estimates ranging from $13.50 million to $29.60 million. For the next year, analysts expect that the company will post sales of $14.51 million per share, with estimates ranging from $11.00 million to $17.54 million. Zacks’ sales averages are an average based on a survey of research firms that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.04. Arrowhead Pharmaceuticals had a negative net margin of 445.30% and a negative return on equity of 66.93%. The company had revenue of $8.99 million during the quarter, compared to the consensus estimate of $4.19 million.

Several equities research analysts have recently issued reports on ARWR shares. Jefferies Group LLC restated a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, April 12th. ValuEngine cut Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $1.80.

Arrowhead Pharmaceuticals (ARWR) traded down 6.36% on Friday, hitting $1.62. 940,231 shares of the stock were exchanged. The company’s market cap is $121.13 million. Arrowhead Pharmaceuticals has a one year low of $1.20 and a one year high of $8.22. The company’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.75.

Institutional investors have recently bought and sold shares of the company. Tudor Investment Corp Et Al bought a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at about $474,000. Geode Capital Management LLC boosted its position in Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 21,654 shares during the period. Vanguard Group Inc. boosted its position in Arrowhead Pharmaceuticals by 13.4% in the first quarter. Vanguard Group Inc. now owns 3,165,579 shares of the biotechnology company’s stock valued at $5,857,000 after buying an additional 374,508 shares during the period. Teachers Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 20.5% in the first quarter. Teachers Advisors LLC now owns 135,684 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 23,042 shares during the period. Finally, SG Americas Securities LLC boosted its position in Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares during the period. Institutional investors own 32.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by sleekmoney and is owned by of sleekmoney. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://sleekmoney.com/analysts-expect-arrowhead-pharmaceuticals-inc-arwr-will-post-quarterly-sales-of-5-29-million/1934828.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/analysts-expect-arrowhead-pharmaceuticals-inc-arwr-will-post-quarterly-sales-of-5-29-million/1934828.html

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *